RCUS - Arcus Biosciences, Inc.
NYSE
->
Healthcare
->
Biotechnology
Hayward,
United States
Type: Equity
RCUS price evolution
RCUS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $156 | $185 | $127 | |
| Short term investments | $813 | $810 | $632 | |
| Net receivables | $21 | $28 | $35 | $38 |
| Inventory | ||||
| Total current assets | $1127 | $1022 | $1064 | $831 |
| Long term investments | $40 | $100 | $107 | |
| Property, plant & equipment | $48 | $49 | $51 | $51 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $164 | $229 | $264 | |
| Total investments | $853 | $910 | $739 | |
| Total assets | $1252 | $1186 | $1293 | $1095 |
| Current liabilities | ||||
| Accounts payable | $13 | $15 | $16 | $17 |
| Deferred revenue | $327 | $366 | $398 | |
| Short long term debt | ||||
| Total current liabilities | $215 | $199 | $204 | $184 |
| Long term debt | $47 | |||
| Total noncurrent liabilities | $352 | $382 | $449 | |
| Total debt | ||||
| Total liabilities | $687 | $551 | $586 | $633 |
| Shareholders' equity | ||||
| Retained earnings | -$1038 | -$946 | -$853 | -$849 |
| Other shareholder equity | $1 | -$1 | -$1 | |
| Total shareholder equity | $635 | $707 | $462 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $127 | $206 | $150.92 | $173.62 |
| Short term investments | $632 | $803 | $351.39 | $555.23 |
| Net receivables | $38 | $39 | $744.6 | $1.05 |
| Inventory | ||||
| Total current assets | $831 | $1067 | $1261.75 | $735.82 |
| Long term investments | $107 | $129 | $181.99 | $6.44 |
| Property, plant & equipment | $51 | $135 | $137.42 | $23.59 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $264 | $278 | $330.15 | $36.48 |
| Total investments | $739 | $932 | $533.38 | $561.67 |
| Total assets | $1095 | $1345 | $1591.9 | $772.29 |
| Current liabilities | ||||
| Accounts payable | $17 | $20 | $10.26 | $15.68 |
| Deferred revenue | $398 | $452 | $564.22 | $197.4 |
| Short long term debt | ||||
| Total current liabilities | $184 | $193 | $166.08 | $121.67 |
| Long term debt | $116.89 | $15.24 | ||
| Total noncurrent liabilities | $449 | $495 | $584.36 | $148.32 |
| Total debt | $116.89 | $15.24 | ||
| Total liabilities | $633 | $688 | $750.45 | $269.99 |
| Shareholders' equity | ||||
| Retained earnings | -$849 | -$542 | -$275.35 | -$328.18 |
| Other shareholder equity | -$7 | -$1.26 | $0.04 | |
| Total shareholder equity | $462 | $657 | $841.45 | $502.3 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $48 | $39 | $145 | $31 |
| Cost of revenue | ||||
| Gross Profit | $39 | $145 | $31 | |
| Operating activities | ||||
| Research & development | $115 | $109 | $93 | |
| Selling, general & administrative | $30 | $32 | $29 | |
| Total operating expenses | $153 | $145 | $161 | $122 |
| Operating income | -$106 | -$16 | -$91 | |
| Income from continuing operations | ||||
| EBIT | -$93 | -$4 | -$80 | |
| Income tax expense | $1 | |||
| Interest expense | $14 | |||
| Net income | ||||
| Net income | -$92 | -$93 | -$4 | -$81 |
| Income (for common shares) | -$93 | -$4 | -$81 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $117 | $112 | $382.88 | $77.52 |
| Cost of revenue | ||||
| Gross Profit | $117 | $112 | $382.88 | $77.52 |
| Operating activities | ||||
| Research & development | $340 | $288 | $256.35 | $159.35 |
| Selling, general & administrative | $117 | $104 | $72.29 | $42.4 |
| Total operating expenses | $457 | $392 | $328.63 | $201.75 |
| Operating income | -$340 | -$280 | $54.25 | -$124.23 |
| Income from continuing operations | ||||
| EBIT | -$301 | -$266 | $54.65 | -$122.86 |
| Income tax expense | $6 | $1 | $1.81 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$307 | -$267 | $52.83 | -$122.86 |
| Income (for common shares) | -$307 | -$267 | $52.83 | -$122.86 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$93 | -$4 | -$81 | |
| Operating activities | ||||
| Depreciation | $4 | $5 | $5 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $20 | $20 | $18 | |
| Total cash flows from operations | -$94 | -$2 | -$88 | |
| Investing activities | ||||
| Capital expenditures | -$4 | -$6 | ||
| Investments | $63 | -$165 | $34 | |
| Total cash flows from investing | -$135 | $63 | -$169 | $28 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3 | $229 | $3 | |
| Net borrowings | ||||
| Total cash flows from financing | $279 | $2 | $229 | $3 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $74 | -$29 | $58 | -$57 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$307 | -$267 | $52.83 | -$122.86 |
| Operating activities | ||||
| Depreciation | $16 | $14 | $7.06 | $4.19 |
| Business acquisitions & disposals | -$3 | |||
| Stock-based compensation | $73 | $65 | $54.53 | $21.82 |
| Total cash flows from operations | -$306 | $438 | -$256.17 | $111.17 |
| Investing activities | ||||
| Capital expenditures | -$24 | -$6 | -$26.08 | -$3.06 |
| Investments | $218 | -$404 | $22.21 | -$431.31 |
| Total cash flows from investing | $194 | -$413 | -$3.87 | -$434.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $33 | $23 | $232.34 | $438.68 |
| Net borrowings | ||||
| Total cash flows from financing | $33 | $33 | $237.34 | $438.68 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$79 | $58 | -$22.7 | $115.48 |
News
Fundamentals
| Market cap | $1.20B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 91.50M |
| Revenue | $263.00M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$270.00M |
| Revenue Q/Q | 50.00% |
| Revenue Y/Y | 119.80% |
| P/E ratio | -4.44 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 4.56 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.95 |
|---|---|
| ROA | -22.38% |
| ROE | N/A |
| Debt/Equity | 1.37 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.24 |
| Quick ratio | N/A |